URGN News and Press, UroGen Pharma Ltd. From 05/13/24

2024-05-13 18:30:56 ET UroGen Pharma Ltd. (URGN) Q1 2024 Earnings Conference Call May 13, 2024 10:00 AM ET Company Participants Vincent Perrone - Head of IR Elizabeth Barrett - President & CEO Mark Schoenberg - Chief Medical Officer Don Kim - CFO Jeff...

2024-05-13 08:06:19 ET More on UroGen Pharma UroGen: All Eyes On UGN-102 UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript Urogen files patent suit against Teva over cancer therapy UroGen Pharma reports mixed Q4 results; initiates FY24 outlook ...

12-month duration of response data from ENVISION study of UGN-102 to be discussed during company sponsored virtual event on June 13, 2024 ENVISION data expected to support completion of UGN-102 NDA in Q3 2024 Post-hoc analysis of OLYMPUS study for JELMYTO shows disease-free period...

Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...

2024-05-10 12:48:02 ET More on UroGen Pharma UroGen: All Eyes On UGN-102 UroGen Pharma Ltd. (URGN) Q4 2023 Earnings Call Transcript Urogen files patent suit against Teva over cancer therapy UroGen Pharma reports mixed Q4 results; initiates FY24 outlook ...

There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or Tumor Location RFS Was 100% in Patients who Received Maintenance therapy vs 61% for Patients Who Did Not Receive Maintenance Therapy UroGen Pharma Ltd. (Nasd...

New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today ann...

60% Complete Response Rate after JELMYTO Induction 25% of Patients Received a Ureteral Stent UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the resul...

Conference Call and Webcast Scheduled for Monday, May 13, 2024, at 10:00AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first...

Subgroup analysis of the UGN-102 ATLAS Trial in patients with new versus recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) Three independent long-term real-world analyses of JELMYTO® (mitomycin) for pyelocalyceal solution exploring its use in broad pa...